Ctrl K
INDP trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes INDP achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 2 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 9, 2026, Indaptus Therapeutics, Inc. (INDP) has a Wall Street consensus price target of N/A, based on estimates from 2 covering analysts. The company has a market capitalization of $215M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 2 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, INDP trades at a trailing P/E of -0.1x. Analysts expect EPS to grow -4674.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IMVTImmunovant, Inc. | $8.2B | $39.57 | $40.00 | +1.1% | Buy | — | 23 |
 KYMRKymera Therapeutics, Inc. | $9.6B | $116.47 | $132.82 | +14.0% | Buy | — | 27 |
 RCUSArcus Biosciences, Inc. | $3.7B | $29.06 | $39.17 | +34.8% | Buy | — | 18 |
 TGTXTG Therapeutics, Inc. | $8.5B | $55.74 | $80.50 | +44.4% | Buy | 55.6x | 13 |
 NKTXNkarta, Inc. | $231M | $3.23 | $9.00 | +178.6% | Buy | — | 12 |
 CRVSCorvus Pharmaceuticals, Inc. | $1.2B | $13.93 | $40.00 | +187.2% | Buy | — | 13 |
 AGENAgenus Inc. | $309M | $7.43 | $25.00 | +236.5% | Buy | 9.6x | 11 |
 IOVAIovance Biotherapeutics, Inc. | $3.9B | $8.70 | $7.83 | -10.0% | Buy | — | 21 |
 FATEFate Therapeutics, Inc. | $291M | $2.50 | $5.63 | +125.2% | Buy | — | 31 |
 MGNXMacroGenics, Inc. | $275M | $4.32 | $6.00 | +38.9% | Buy | — | 22 |
Quick answers to the most common questions about buying INDP stock.
The consensus price target for INDP is $N/A, close to the current price of $1.85 (N/A% implied move). Based on 2 analyst estimates, the stock appears fairly valued near current levels.
INDP has a consensus rating of "Buy" based on 2 Wall Street analysts. The rating breakdown is predominantly bullish, with 2 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
INDP's current price is $1.85 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $N/A for INDP, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
INDP is lightly followed, with 2 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 2 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month INDP stock forecast based on 2 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
INDP appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
INDP analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.